Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 526-542

  Giovacchini, Giampiero ^a   Nicolas, Guillaume ^a   Forrer, Flavio ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Neuroendocrine tumors; Peptide receptor radionuclide therapy; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; DOTATATE; DOTATOC; FLUORODEOXYGLUCOSE F 18; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; TETRAXETAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BINDING AFFINITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CELL DIFFERENTIATION; DOSIMETRY; DRUG EFFICACY; DRUG TOLERABILITY; GLUCOSE METABOLISM; HUMAN; LIVER DISEASE; LIVER TOXICITY; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84861665921     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617803     Document Type: Article

References (148)

1. Modlin, I.M.; Oberg, K.; Chung, D.C.; Jensen, R.T.; de Herder, W.W.; Thakker, R.V.; Caplin, M.; Delle Fave, G.; Kaltsas, G.A.; Krenning, E.P.; Moss, S.F.; Nilsson, O.; Rindi, G.; Salazar, R.; Ruszniewski, P.; Sundin, A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol., 2008, 9(1), 61-72.
2. Wiedenmann, B.; John, M.; Ahnert-Hilger, G.; Riecken, E.O. Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J. Mol. Med., 1998, 76(9), 637-647.
3. Zikusoka, M.N.; Kidd, M.; Eick, G.; Latich, I.; Modlin, I.M. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer, 2005, 104(11), 2292-2309.
4. Forrer, F.; Riedweg, I.; Maecke, H.R.; Mueller-Brand, J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 334-340.
5. Reubi, J.C. Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J. Biol. Med., 1992, 65(5), 493-503.
6. Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24(4), 389-427.
7. Williams, E.D.; Sandler, M. The classification of carcinoid tum ours. Lancet, 1963, 1(7275), 238-239.
8. Plockinger, U.; Gustafsson, B.; Ivan, D.; Szpak, W.; Davar, J. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography. Neuroendocrinology, 2009, 90(2), 190-193.
9. Rindi, G.; Kloppel, G.; Alhman, H.; Caplin, M.; Couvelard, A.; de Herder, W.W.; Erikssson, B.; Falchetti, A.; Falconi, M.; Komminoth, P.; Korner, M.; Lopes, J.M.; McNicol, A.M.; Nilsson, O.; Perren, A.; Scarpa, A.; Scoazec, J.Y.; Wiedenmann, B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch., 2006, 449(4), 395-401.
10. Quaedvlieg, P.F.; Visser, O.; Lamers, C.B.; Janssen-Heijen, M.L.; Taal, B.G. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann. Oncol., 2001, 12(9), 1295-1300.
11. Modlin, I.M.; Lye, K.D.; Kidd, M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 2003, 97(4), 934-959.
12. Janson, E.T.; Holmberg, L.; Stridsberg, M.; Eriksson, B.; Theodorsson, E.; Wilander, E.; Oberg, K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol., 1997, 8(7), 685-690.
13. Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med., 2001, 28(7), 836-846.
14. Behr, T.M.; Gotthardt, M.; Barth, A.; Behe, M. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med., 2001, 45(2), 189-200.
15. Ambrosini, V.; Tomassetti, P.; Franchi, R.; Fanti, S. Imaging of NETs with PET radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 16-23.
16. Gibril, F.; Jensen, R.T. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig. Liver Dis., 2004, 36(Suppl 1), S106-120.
17. Norton, J.A.; Fraker, D.L.; Alexander, H.R.; Gibril, F.; Liewehr, D.J.; Venzon, D.J.; Jensen, R.T. Surgery increases survival in patients with gastrinoma. Ann. Surg., 2006, 244(3), 410-419.
18. Akerstrom, G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J. Surg., 1996, 20(2), 173-182.
19. Arnold, R.; Simon, B.; Wied, M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion, 2000, 62(Suppl 1), 84-91.
20. Hejna, M.; Schmidinger, M.; Raderer, M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Oncol., 2002, 13(5), 653-668.
21. Panzuto, F.; Di Fonzo, M.; Iannicelli, E.; Sciuto, R.; Maini, C.L.; Capurso, G.; Milione, M.; Cattaruzza, M.S.; Falconi, M.; David, V.; Ziparo, V.; Pederzoli, P.; Bordi, C.; Delle Fave, G. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann. Oncol., 2006, 17(3), 461-466.
22. Rinke, A.; Muller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Blaker, M.; Harder, J.; Arnold, C.; Gress, T.; Arnold, R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin. Oncol., 2009, 27(28), 4656-4663.
23. Eriksson, B.; Janson, E.T.; Bax, N.D.; Mignon, M.; Morant, R.; Opolon, P.; Rougier, P.; Oberg, K.E. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumours. Digestion, 1996, 57(Suppl 1), 77-80.
24. Oberg, K.; Ferone, D.; Kaltsas, G.; Knigge, U.P.; Taal, B.; Plockinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology, 2009, 90(2), 209-213.
25. Shah, T.; Caplin, M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract. Res. Clin. Gastroenterol., 2005, 19(4), 617-636.
26. Faiss, S.; Pape, U.F.; Bohmig, M.; Dorffel, Y.; Mansmann, U.; Golder, W.; Riecken, E.O.; Wiedenmann, B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin. Oncol., 2003, 21(14), 2689-2696.
27. Eriksson, B.; Annibale, B.; Bajetta, E.; Mitry, E.; Pavel, M.; Platania, M.; Salazar, R.; Plockinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology, 2009, 90(2), 214-219.
28. Kouvaraki, M.A.; Ajani, J.A.; Hoff, P.; Wolff, R.; Evans, D.B.; Lozano, R.; Yao, J.C. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin. Oncol., 2004, 22(23), 4762-4771.
29. Krenning, E.P.; de Jong, M.; Kooij, P.P.; Breeman, W.A.; Bakker, W.H.; de Herder, W.W.; van Eijck, C.H.; Kwekkeboom, D.J.; Jamar, F.; Pauwels, S.; Valkema, R. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol., 1999, 10(Suppl 2), S23-29.
30. Bodei, L.; Handkiewicz-Junak, D.; Grana, C.; Mazzetta, C.; Rocca, P.; Bartolomei, M.; Lopera Sierra, M.; Cremonesi, M.; Chinol, M.; Macke, H.R.; Paganelli, G. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother. Radiopharm., 2004, 19(1), 65-71.
31. Bodei, L.; Cremonesi, M.; Grana, C.; Rocca, P.; Bartolomei, M.; Chinol, M.; Paganelli, G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(7), 1038-1046.
32. Valkema, R.; Pauwels, S.; Kvols, L.K.; Barone, R.; Jamar, F.; Bakker, W.H.; Kwekkeboom, D.J.; Bouterfa, H.; Krenning, E.P. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med., 2006, 36(2), 147-156.
33. Kwekkeboom, D.J.; Bakker, W.H.; Kam, B.L.; Teunissen, J.J.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; de Jong, M.; Srinivasan, A.; Erion, J.L.; Krenning, E.P. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3] octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(3), 417-422.
34. Waser, B.; Tamma, M.L.; Cescato, R.; Maecke, H.R.; Reubi, J.C. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J. Nucl. Med., 2009, 50(6), 936-941.
35. Fjalling, M.; Andersson, P.; Forssell-Aronsson, E.; Gretarsdottir, J.; Johansson, V.; Tisell, L.E.; Wangberg, B.; Nilsson, O.; Berg, G.; Michanek, A.; Lindstedt, G.; Ahlman, H. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J. Nucl. Med., 1996, 37(9), 1519-1521.
36. Kwekkeboom, D.; Krenning, E.P.; de Jong, M. Peptide receptor imaging and therapy. J. Nucl. Med., 2000, 41(10), 1704-1713.
37. Valkema, R.; De Jong, M.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Lugtenburg, P.J.; De Jong, F.H.; Christiansen, A.; Kam, B.L.; De Herder, W.W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E.P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med., 2002, 32(2), 110-122.
38. De Jong, M.; Valkema, R.; Jamar, F.; Kvols, L.K.; Kwekkeboom, D.J.; Breeman, W.A.; Bakker, W.H.; Smith, C.; Pauwels, S.; Krenning, E.P. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med., 2002, 32(2), 133-140.
39. Mariani, G.; Bodei, L.; Adelstein, S.J.; Kassis, A.I. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J. Nucl. Med., 2000, 41(9), 1519-1521.
40. Janson, E.T.; Westlin, J.E.; Ohrvall, U.; Oberg, K.; Lukinius, A. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J. Nucl. Med., 2000, 41(9), 1514-1518.
41. Rufini, V.; Calcagni, M.L.; Baum, R.P. Imaging of neuroendocrine tumors. Semin. Nucl. Med., 2006, 36(3), 228-247.
42. Schottelius, M.; Wester, H.J. Molecular imaging targeting peptide receptors. Methods, 2009, 48(2), 161-177.
43. Forrer, F.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M.; Krenning, E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21(1), 111-129.
44. Reubi, J.C.; Schar, J.C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Macke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27(3), 273-282.
45. Hofmann, M.; Maecke, H.; Borner, R.; Weckesser, E.; Schoffski, P.; Oei, L.; Schumacher, J.; Henze, M.; Heppeler, A.; Meyer, J.; Knapp, H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med., 2001, 28(12), 1751-1757.
46. Maecke, H.R.; Hofmann, M.; Haberkorn, U. (68)Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005, 46(Suppl 1), 172S-178S.
47. Wester, H.J.; Schottelius, M.; Scheidhauer, K.; Meisetschlager, G.; Herz, M.; Rau, F.C.; Reubi, J.C.; Schwaiger, M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(1), 117-122.
48. Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; Von Guggenberg, E.; Bale, R.; Virgolini, I.J. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med., 2007, 48(4), 508-518.
49. Buchmann, I.; Henze, M.; Engelbrecht, S.; Eisenhut, M.; Runz, A.; Schafer, M.; Schilling, T.; Haufe, S.; Herrmann, T.; Haberkorn, U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(10), 1617-1626.
50. Ambrosini, V.; Campana, D.; Bodei, L.; Nanni, C.; Castellucci, P.; Allegri, V.; Montini, G.C.; Tomassetti, P.; Paganelli, G.; Fanti, S. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J. Nucl. Med., 2010, 51(5), 669-673.
51. Gabriel, M.; Oberauer, A.; Dobrozemsky, G.; Decristoforo, C.; Putzer, D.; Kendler, D.; Uprimny, C.; Kovacs, P.; Bale, R.; Virgolini, I.J. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J. Nucl. Med., 2009, 50(9), 1427-1434.
52. Baum, R.P.; Prasad, V.; Hommann, M.; Horsch, D. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res., 2008, 170(225-242.
53. de Jong, M.; Breeman, W.A.; Valkema, R.; Bernard, B.F.; Krenning, E.P. Combination radionuclide therapy using 177Luand 90Y-labeled somatostatin analogs. J. Nucl. Med., 2005, 46(Suppl 1), 13S-17S.
54. Konijnenberg, M.W.; Bijster, M.; Krenning, E.P.; De Jong, M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J. Nucl. Med., 2004, 45(7), 1260-1269.
55. Kwekkeboom, D.J.; Teunissen, J.J.; Bakker, W.H.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; Esser, J.P.; Kam, B.L.; Krenning, E.P. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin. Oncol., 2005, 23(12), 2754-2762.
56. Forrer, F.; Uusijarvi, H.; Storch, D.; Maecke, H.R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J. Nucl. Med., 2005, 46(8), 1310-1316.
57. Kwekkeboom, D.J.; Krenning, E.P.; Scheidhauer, K.; Lewington, V.; Lebtahi, R.; Grossman, A.; Vitek, P.; Sundin, A.; Plockinger, U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology, 2009, 90(2), 184-189.
58. Miller, A.B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. Cancer, 1981, 47(1), 207-214.
59. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92(3), 205-216.
60. Green, S.; Weiss, G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs, 1992, 10(4), 239-253.
61. Krenning, E.P.; Kwekkeboom, D.J.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Oei, H.Y.; van Hagen, M.; Postema, P.T.; de Jong, M.; Reubi, J.C.; et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 1993, 20(8), 716-731.
62. Krenning, E.P.; Kooij, P.P.; Bakker, W.H.; Breeman, W.A.; Postema, P.T.; Kwekkeboom, D.J.; Oei, H.Y.; de Jong, M.; Visser, T.J.; Reijs, A.E.; et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann. N. Y. Acad. Sci., 1994, 733(496-506.
63. Anthony, L.B.; Woltering, E.A.; Espenan, G.D.; Cronin, M.D.; Maloney, T.J.; McCarthy, K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med., 2002, 32(2), 123-132.
64. Delpassand, E.S.; Sims-Mourtada, J.; Saso, H.; Azhdarinia, A.; Ashoori, F.; Torabi, F.; Espenan, G.; Moore, W.H.; Woltering, E.; Anthony, L. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother. Radiopharm., 2008, 23(3), 292-300.
65. Oberg, K.; Eriksson, B. Endocrine tumours of the pancreas. Best Pract. Res. Clin. Gastroenterol., 2005, 19(5), 753-781.
66. Mardirossian, G.; Wu, C.; Hnatowich, D.J. The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. Nucl. Med. Biol., 1993, 20(1), 65-74.
67. Liu, S.; Edwards, D.S. Stabilization of (90)y-labeled DOTAbiomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug. Chem., 2001, 12(4), 554-558.
68. Otte, A.; Jermann, E.; Behe, M.; Goetze, M.; Bucher, H.C.; Roser, H.W.; Heppeler, A.; Mueller-Brand, J.; Maecke, H.R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med., 1997, 24(7), 792-795.
69. Otte, A.; Mueller-Brand, J.; Dellas, S.; Nitzsche, E.U.; Herrmann, R.; Maecke, H.R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet, 1998, 351(9100), 417-418.
70. Otte, A.; Herrmann, R.; Heppeler, A.; Behe, M.; Jermann, E.; Powell, P.; Maecke, H.R.; Muller, J. Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med., 1999, 26(11), 1439-1447.
71. Waldherr, C.; Pless, M.; Maecke, H.R.; Haldemann, A.; Mueller-Brand, J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol., 2001, 12(7), 941-945.
72. Waldherr, C.; Pless, M.; Maecke, H.R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E.U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med., 2002, 43(5), 610-616.
73. Forrer, F.; Waldherr, C.; Maecke, H.R.; Mueller-Brand, J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res., 2006, 26(1B), 703-707.
74. Bodei, L.; Cremonesi, M.; Zoboli, S.; Grana, C.; Bartolomei, M.; Rocca, P.; Caracciolo, M.; Macke, H.R.; Chinol, M.; Paganelli, G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(2), 207-216.
75. Virgolini, I.; Britton, K.; Buscombe, J.; Moncayo, R.; Paganelli, G.; Riva, P. In-and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med., 2002, 32(2), 148-155.
76. Cwikla, J.B.; Sankowski, A.; Seklecka, N.; Buscombe, J.R.; Nasierowska-Guttmejer, A.; Jeziorski, K.G.; Mikolajczak, R.; Pawlak, D.; Stepien, K.; Walecki, J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann. Oncol., 2010, 21(4), 787-794.
77. Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin. Oncol., 2008, 26(13), 2124-2130.
78. Esser, J.P.; Krenning, E.P.; Teunissen, J.J.; Kooij, P.P.; van Gameren, A.L.; Bakker, W.H.; Kwekkeboom, D.J. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(11), 1346-1351.
79. Forrer, F.; Uusijarvi, H.; Waldherr, C.; Cremonesi, M.; Bernhardt, P.; Mueller-Brand, J.; Maecke, H.R. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(9), 1257-1262.
80. Frilling, A.; Weber, F.; Saner, F.; Bockisch, A.; Hofmann, M.; Mueller-Brand, J.; Broelsch, C.E. Treatment with (90)Y-and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 2006, 140(6), 968-976.
81. Seregni, E.; Maccauro, M.; Coliva, A.; Castellani, M.R.; Bajetta, E.; Aliberti, G.; Vellani, C.; Chiesa, C.; Martinetti, A.; Bogni, A.; Bombardieri, E. Treatment with tandem [90Y]DOTA-TATE an [177Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 84-91.
82. Brans, B.; Bodei, L.; Giammarile, F.; Linden, O.; Luster, M.; Oyen, W.J.; Tennvall, J. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(5), 772-786.
83. Stabin, M.G.; Sparks, R.B.; Crowe, E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 2005, 46(6), 1023-1027.
84. Pauwels, S.; Barone, R.; Walrand, S.; Borson-Chazot, F.; Valkema, R.; Kvols, L.K.; Krenning, E.P.; Jamar, F. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J. Nucl. Med., 2005, 46(Suppl 1), 92S-98S.
85. Jamar, F.; Barone, R.; Mathieu, I.; Walrand, S.; Labar, D.; Carlier, P.; de Camps, J.; Schran, H.; Chen, T.; Smith, M.C.; Bouterfa, H.; Valkema, R.; Krenning, E.P.; Kvols, L.K.; Pauwels, S. 86YDOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(4), 510-518.
86. Barone, R.; Borson-Chazot, F.; Valkema, R.; Walrand, S.; Chauvin, F.; Gogou, L.; Kvols, L.K.; Krenning, E.P.; Jamar, F.; Pauwels, S. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J. Nucl. Med., 2005, 46(Suppl 1), 99S-106S.
87. DeNardo, G.L.; Juweid, M.E.; White, C.A.; Wiseman, G.A.; DeNardo, S.J. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit. Rev. Oncol. Hematol., 2001, 39(1-2), 203-218.
88. Dale, R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother. Radiopharm., 2004, 19(3), 363-370.
89. Wessels, B.W.; Konijnenberg, M.W.; Dale, R.G.; Breitz, H.B.; Cremonesi, M.; Meredith, R.F.; Green, A.J.; Bouchet, L.G.; Brill, A.B.; Bolch, W.E.; Sgouros, G.; Thomas, S.R. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J. Nucl. Med., 2008, 49(11), 1884-1899.
90. Emami, B.; Lyman, J.; Brown, A.; Coia, L.; Goitein, M.; Munzenrider, J.E.; Shank, B.; Solin, L.J.; Wesson, M. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys., 1991, 21(1), 109-122.
91. Konijnenberg, M.W. Is the renal dosimetry for [90YDOTA0, Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother. Radiopharm., 2003, 18(4), 619-625.
92. Cremonesi, M.; Botta, F.; Di Dia, A.; Ferrari, M.; Bodei, L.; De Cicco, C.; Rossi, A.; Bartolomei, M.; Mei, R.; Severi, S.; Salvatori, M.; Pedroli, G.; Paganelli, G. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 37-51.
93. Forster, G.J.; Engelbach, M.J.; Brockmann, J.J.; Reber, H.J.; Buchholz, H.G.; Macke, H.R.; Rosch, F.R.; Herzog, H.R.; Bartenstein, P.R. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur. J. Nucl. Med., 2001, 28(12), 1743-1750.
94. Breeman, W.A.; de Jong, M.; de Blois, E.; Bernard, B.F.; Konijnenberg, M.; Krenning, E.P. Radiolabelling DOTApeptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(4), 478-485.
95. Ambrosini, V.; Nanni, C.; Zompatori, M.; Campana, D.; Tomassetti, P.; Castellucci, P.; Allegri, V.; Rubello, D.; Montini, G.; Franchi, R.; Fanti, S. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(4), 722-727.
96. Kwekkeboom, D.J.; de Herder, W.W.; Krenning, E.P. Receptor imaging in the diagnosis and treatment of pituitary tumors. J. Endocrinol. Invest., 1999, 22(1), 80-88.
97. Cremonesi, M.; Ferrari, M.; Bodei, L.; Tosi, G.; Paganelli, G. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides. Q. J. Nucl. Med. Mol. Imaging, 2006, 50(4), 288-295.
98. Kwekkeboom, D.J.; Kooij, P.P.; Bakker, W.H.; Macke, H.R.; Krenning, E.P. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med., 1999, 40(5), 762-767.
99. Fabbri, C.; Sarti, G.; Cremonesi, M.; Ferrari, M.; Di Dia, A.; Agostini, M.; Botta, F.; Paganelli, G. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patientspecific dosimetry. Cancer Biother. Radiopharm., 2009, 24(1), 145-154.
100. Lhommel, R.; Goffette, P.; Van den Eynde, M.; Jamar, F.; Pauwels, S.; Bilbao, J.I.; Walrand, S. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(10), 1696.
101. Werner, M.K.; Brechtel, K.; Beyer, T.; Dittmann, H.; Pfannenberg, C.; Kupferschlager, J. PET/CT for the assessment and quantification of (90)Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(2), 407-408.
102. Moertel, C.G.; Hanley, J.A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials, 1979, 2(4), 327-334.
103. Engstrom, P.F.; Lavin, P.T.; Moertel, C.G.; Folsch, E.; Douglass, H.O., Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin. Oncol., 1984, 2(11), 1255-1259.
104. Forrer, F.; Krenning, E.P.; Kooij, P.P.; Bernard, B.F.; Konijnenberg, M.; Bakker, W.H.; Teunissen, J.J.; de Jong, M.; van Lom, K.; de Herder, W.W.; Kwekkeboom, D.J. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(7), 1138-1146.
105. Konijnenberg, M.; Melis, M.; Valkema, R.; Krenning, E.; de Jong, M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J. Nucl. Med., 2007, 48(1), 134-142.
106. Forrer, F.; Rolleman, E.; Bijster, M.; Melis, M.; Bernard, B.; Krenning, E.P.; de Jong, M. From outside to inside? Dosedependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother. Radiopharm., 2007, 22(1), 40-49.
107. de Jong, M.; Barone, R.; Krenning, E.; Bernard, B.; Melis, M.; Visser, T.; Gekle, M.; Willnow, T.E.; Walrand, S.; Jamar, F.; Pauwels, S. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J. Nucl. Med., 2005, 46(10), 1696-1700.
108. Mogensen, C.E.; Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand. J. Clin. Lab. Invest., 1977, 37(6), 477-486.
109. De Jong, M.; Valkema, R.; Van Gameren, A.; Van Boven, H.; Bex, A.; Van De Weyer, E.P.; Burggraaf, J.D.; Korner, M.; Reubi, J.C.; Krenning, E.P. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J. Nucl. Med., 2004, 45(7), 1168-1171.
110. Bodei, L.; Cremonesi, M.; Ferrari, M.; Pacifici, M.; Grana, C.M.; Bartolomei, M.; Baio, S.M.; Sansovini, M.; Paganelli, G. Longterm evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(10), 1847-1856.
111. Valkema, R.; Pauwels, S.A.; Kvols, L.K.; Kwekkeboom, D.J.; Jamar, F.; de Jong, M.; Barone, R.; Walrand, S.; Kooij, P.P.; Bakker, W.H.; Lasher, J.; Krenning, E.P. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)YDOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J. Nucl. Med., 2005, 46(Suppl 1), 83S-91S.
112. Barone, R.; Pauwels, S.; De Camps, J.; Krenning, E.P.; Kvols, L.K.; Smith, M.C.; Bouterfa, H.; Devuyst, O.; Jamar, F. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol. Dial. Transplant, 2004, 19(9), 2275-2281.
113. Rolleman, E.J.; Valkema, R.; de Jong, M.; Kooij, P.P.; Krenning, E.P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(1), 9-15.
114. Bernard, B.F.; Krenning, E.P.; Breeman, W.A.; Rolleman, E.J.; Bakker, W.H.; Visser, T.J.; Macke, H.; de Jong, M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J. Nucl. Med., 1997, 38(12), 1929-1933.
115. Vegt, E.; Wetzels, J.F.; Russel, F.G.; Masereeuw, R.; Boerman, O.C.; van Eerd, J.E.; Corstens, F.H.; Oyen, W.J. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J. Nucl. Med., 2006, 47(3), 432-436.
116. van Eerd, J.E.; Vegt, E.; Wetzels, J.F.; Russel, F.G.; Masereeuw, R.; Corstens, F.H.; Oyen, W.J.; Boerman, O.C. Gelatin-based plasma expander effectively reduces renal uptake of 111Inoctreotide in mice and rats. J. Nucl. Med., 2006, 47(3), 528-533.
117. Vegt, E.; van Eerd, J.E.; Eek, A.; Oyen, W.J.; Wetzels, J.F.; de Jong, M.; Russel, F.G.; Masereeuw, R.; Gotthardt, M.; Boerman, O.C. Reducing renal uptake of radiolabeled peptides using albumin fragments. J. Nucl. Med., 2008, 49(9), 1506-1511.
118. Rolleman, E.J.; Forrer, F.; Bernard, B.; Bijster, M.; Vermeij, M.; Valkema, R.; Krenning, E.P.; de Jong, M. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(5), 763-771.
119. Moll, S.; Nickeleit, V.; Mueller-Brand, J.; Brunner, F.P.; Maecke, H.R.; Mihatsch, M.J. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am. J. Kidney Dis., 2001, 37(4), 847-851.
120. Cybulla, M.; Weiner, S.M.; Otte, A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur. J. Nucl. Med., 2001, 28(10), 1552-1554.
121. Kwekkeboom, D.J.; Mueller-Brand, J.; Paganelli, G.; Anthony, L.B.; Pauwels, S.; Kvols, L.K.; O'Dorisio T, M.; Valkema, R.; Bodei, L.; Chinol, M.; Maecke, H.R.; Krenning, E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med., 2005, 46(Suppl 1), 62S-66S.
122. Cremonesi, M.; Ferrari, M.; Zoboli, S.; Chinol, M.; Stabin, M.G.; Orsi, F.; Maecke, H.R.; Jermann, E.; Robertson, C.; Fiorenza, M.; Tosi, G.; Paganelli, G. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur. J. Nucl. Med., 1999, 26(8), 877-886.
123. Sgouros, G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. J. Nucl. Med., 2005, 46(5), 899-900.
124. Virgolini, I.; Kurtaran, A.; Angelberger, P.; Raderer, M.; Havlik, E.; Smith-Jones, P. "MAURITIUS": tumour dose in patients with advanced carcinoma. Ital. J. Gastroenterol. Hepatol., 1999, 31(Suppl 2), S227-230.
125. Caplin, M.E.; Hodgson, H.J.; Dhillon, A.P.; Begent, R.; Buscombe, J.; Dick, R.; Rolles, K.; Burroughs, A.K. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol, 1998, 93(10), 1945-1948.
126. Sierra, M.L.; Agazzi, A.; Bodei, L.; Pacifici, M.; Arico, D.; De Cicco, C.; Quarna, J.; Sansovini, M.; De Simone, M.; Paganelli, G. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother. Radiopharm., 2009, 24(6), 659-665.
127. Benua, R.S.; Cicale, N.R.; Sonenberg, M.; Rawson, R.W. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am. J. Roentgenol. Radium Ther. Nucl. Med., 1962, 87(171-182.
128. Cremonesi, M.; Ferrari, M.; Bodei, L.; Tosi, G.; Paganelli, G. Dosimetry in Peptide radionuclide receptor therapy: a review. J. Nucl. Med., 2006, 47(9), 1467-1475.
129. Bushnell, D.; Menda, Y.; Madsen, M.; O'Dorisio, T.; Carlisle, T.; Zehr, P.; Ponto, L.; Karwal, M.; Parker, S.; Ponto, J.; Connolly, M.; Bouterfa, H. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM) in patients with diffuse somatostatin receptor positive liver metastases. Cancer Biother. Radiopharm., 2003, 18(4), 581-588.
130. Teunissen, J.J.; Krenning, E.P.; de Jong, F.H.; de Rijke, Y.B.; Feelders, R.A.; van Aken, M.O.; de Herder, W.W.; Kwekkeboom, D.J. Effects of therapy with [177Lu-DOTA 0, Tyr 3]octreotate on endocrine function. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(11), 1758-1766.
131. Kaltsas, G.A.; Besser, G.M.; Grossman, A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev., 2004, 25(3), 458-511.
132. Pape, U.F.; Jann, H.; Muller-Nordhorn, J.; Bockelbrink, A.; Berndt, U.; Willich, S.N.; Koch, M.; Rocken, C.; Rindi, G.; Wiedenmann, B. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer, 2008, 113(2), 256-265.
133. Asnacios, A.; Courbon, F.; Rochaix, P.; Bauvin, E.; Cances-Lauwers, V.; Susini, C.; Schulz, S.; Boneu, A.; Guimbaud, R.; Buscail, L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin. Oncol., 2008, 26(6), 963-970.
134. Garin, E.; Le Jeune, F.; Devillers, A.; Cuggia, M.; de Lajarte-Thirouard, A.S.; Bouriel, C.; Boucher, E.; Raoul, J.L. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J. Nucl. Med., 2009, 50(6), 858-864.
135. Binderup, T.; Knigge, U.; Loft, A.; Federspiel, B.; Kjaer, A. 18Ffluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res., 2010, 16(3), 978-985.
136. Clancy, T.E.; Sengupta, T.P.; Paulus, J.; Ahmed, F.; Duh, M.S.; Kulke, M.H. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci., 2006, 51(5), 877-884.
137. Oberg, K.; Norheim, I.; Lundqvist, G.; Wide, L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU. Acta Oncol., 1987, 26(6), 429-432.
138. Teunissen, J.J.; Kwekkeboom, D.J.; Krenning, E.P. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin. Oncol., 2004, 22(13), 2724-2729.
139. Kwekkeboom, D.J.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; van Eijck, C.H.; Valkema, R.; de Jong, M.; de Herder, W.W.; Krenning, E.P. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer, 2010, 17(1), R53-73.
140. Uusijarvi, H.; Bernhardt, P.; Rosch, F.; Maecke, H.R.; Forssell-Aronsson, E. Electron-and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. J. Nucl. Med., 2006, 47(5), 807-814.
141. Norenberg, J.P.; Krenning, B.J.; Konings, I.R.; Kusewitt, D.F.; Nayak, T.K.; Anderson, T.L.; de Jong, M.; Garmestani, K.; Brechbiel, M.W.; Kvols, L.K. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res., 2006, 12(3 Pt 1), 897-903.
142. Ginj, M.; Chen, J.; Walter, M.A.; Eltschinger, V.; Reubi, J.C.; Maecke, H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res., 2005, 11(3), 1136-1145.
143. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H.R.; Reubi, J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(44), 16436-16441.
144. Wild, D.; Fani, M.; Behe, M.; Buchegger-Podbielski, U.; Brink, I.; Rivier, J.; Reubi, J.C.; Maecke, H.; Weber, W.A. First clinical evaluation of a somatostatin receptor antagonist for imaging of neuroendocrine tumors (NETs). Nuklearmedizin, 2010, 49(31), A16.
145. van Putten, J.W.; Price, A.; van der Leest, A.H.; Gregor, A.; Little, F.A.; Groen, H.J. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin. Cancer Res., 2003, 9(7), 2472-2477.
146. Modlin, I.M.; Latich, I.; Kidd, M.; Zikusoka, M.; Eick, G. Therapeutic options for gastrointestinal carcinoids. Clin. Gastroenterol. Hepatol., 2006, 4(5), 526-547.
147. van Essen, M.; Krenning, E.P.; Kam, B.L.; de Herder, W.W.; van Aken, M.O.; Kwekkeboom, D.J. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(4), 743-748.
148. Buscombe, J.R.; Caplin, M.E.; Hilson, A.J. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med., 2003, 44(1), 1-6.